Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder

References

• Substance Abuse and Mental Health Services Administration. 2019 National Survey of Drug Use and Health (NSDUH) releases [cited 2020 Sep 29]. Available from: https://www.samhsa.gov/data/release/2019-national-survey-drug-use-and-health-nsduh-releases.
   Google Scholar
• Centers for Disease Control and Prevention. Wide-ranging online data for epidemiological research (WONDER). National Center on Health Statistics, Center for Disease Control and Prevention [Published 2018. cited 2019 Jul 29]. https://wonder.cdc.gov.
   Google Scholar
• The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med. 2020;14(2S Suppl 1):1–91. DOI:10.1097/ADM.0000000000000633.
   Google Scholar
• Center for Behavioral Health Statistics and Quality. 2017 National survey on drug use and health final analytic file codebook. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2018.
   Google Scholar
• National Academies of Sciences Engineering and Medicine. Medications for opioid use disorder save lives. Washington, DC: The National Academies Press; 2019.
   Google Scholar
• Marsch LA, Dallery J. Advances in the psychosocial treatment of addiction: the role of technology in the delivery of evidence-based psychosocial treatment. Psychiatr Clin North Am. 2012;35(2):481–493.
   PubMed Web of Science ®Google Scholar
• Pincus HA, England MJ. Improving the quality of psychosocial interventions for mental and substance use disorders: a report from the IOM. JAMA.2015;314(12):1227–1228.
   PubMed Web of Science ®Google Scholar
• Budney AJ, Higgins ST. A community reinforcement plus vouchers approach: treating cocaine addiction (NIH Publication Number 98-4309). Rockville (MD): National Institute on Drug Abuse; 1998.
   Google Scholar
• Hunt GM, Azrin NH. A community-reinforcement approach to alcoholism. Behav Res Ther. 1973;11(1):91–104.
   PubMed Web of Science ®Google Scholar
• Bickel WK, Marsch LA, Buchhalter AR, et al. Computerized behavior therapy for opioid-dependent outpatients: a randomized controlled trial. Exp Clin Psychopharmacol. 2008;16(2):132–143.
   PubMed Web of Science ®Google Scholar
• Campbell AN, Nunes EV, Matthews AG, et al. Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatry. 2014;171(6):683–690.
   PubMed Web of Science ®Google Scholar
• Christensen DR, Landes RD, Jackson L, et al. Adding an internet-delivered treatment to an efficacious treatment package for opioid dependence. J Consult Clin Psychol. 2014;82(6):964–972.
   PubMed Web of Science ®Google Scholar
• Stitzer M, Petry N. Contingency management for treatment of substance abuse. Annu Rev Clin Psychol. 2006;2:411–434.
   PubMed Web of Science ®Google Scholar
• Bickel WK, Amass L, Higgins ST, et al. Effects of adding behavioral treatment to opioid detoxification with buprenorphine. J Consult Clin Psychol. 1997;65(5):803–810.
   PubMed Web of Science ®Google Scholar
• Marsch LA, Guarino H, Acosta M, et al. Web-based behavioral treatment for substance use disorders as a partial replacement of standard methadone maintenance treatment. J Subst Abuse Treat. 2014;46(1):43–51.
   PubMed Web of Science ®Google Scholar
• National Institute on Drug Abuse. Principles of drug addiction treatment. A research based guide. Rockville (MD): National Institutes of Health, US Department of Health and Human Services; 2012. p. 1–75.
   Google Scholar
• Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment improvement protocol (TIP) series 40. DHHS Publication No. (SMA) 04-3939. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2004.
   Google Scholar
• Marsch LA, Bickel WK, Badger GJ, et al. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing. Drug Alcohol Depend. 2005;77(2):195–204.
   PubMed Web of Science ®Google Scholar
• Center for Devices and Radiological Health. De Novo summary for reSET (DEN160018). Washington, DC: US Food and Drug Administration; 2017.
   Google Scholar
• Clinical Trials Network. Treatment Effect & Assessment Measures (TEAM) Task Force Recommendations. 2010 [cited 2020 Nov 6]. Available from: http://ctndisseminationlibrary.org/PDF/522.pdf
   Google Scholar
• Hser YI, Evans E, Huang D, et al. Relationship between drug treatment services, retention, and outcomes. Psychiatr Serv. 2004;55(7):767–774.
   PubMed Web of Science ®Google Scholar
• Cunningham C, Stitzer M, Campbell AN, et al. Contingency management abstinence incentives: cost and implications for treatment tailoring. J Subst Abuse Treat. 2017;72:134–139.
   PubMed Web of Science ®Google Scholar
• Kaskutas LA, Borkman TJ, Laudet A, et al. Elements that define recovery: the experiential perspective. J Stud Alcohol Drugs. 2014;75(6):999–1010.
   PubMed Web of Science ®Google Scholar
• Laudet AB. What does recovery mean to you? Lessons from the recovery experience for research and practice. J Subst Abuse Treat. 2007;33(3):243–256.
   PubMed Web of Science ®Google Scholar
• Dennis ML, Foss MA, Scott CK. An eight-year perspective on the relationship between the duration of abstinence and other aspects of recovery. Eval Rev. 2007;31(6):585–612.
   PubMed Web of Science ®Google Scholar
• Weisner C, Ray GT, Mertens JR, et al. Short-term alcohol and drug treatment outcomes predict long-term outcome. Drug Alcohol Depend. 2003;71(3):281–294.
   PubMed Web of Science ®Google Scholar
• Hser YI, Evans E, Huang D, et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016;111(4):695–705.
   PubMed Web of Science ®Google Scholar
• Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79–87.
   PubMed Web of Science ®Google Scholar
• Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238–1246.
   PubMed Web of Science ®Google Scholar
• Soeffing JM, Martin LD, Fingerhood MI, et al. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat. 2009;37(4):426–430.
   PubMed Web of Science ®Google Scholar
• Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005;20(11):1038–1041.
   PubMed Web of Science ®Google Scholar
• Hubbard RL, Craddock SG, Anderson J. Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). J Subst Abuse Treat. 2003;25(3):125–134.
   PubMed Web of Science ®Google Scholar
• Simpson DD. The relation of time spent in drug abuse treatment to posttreatment outcome. Am J Psychiatry. 1979;136(11):1449–1453.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction. 2003;98(5):673–684.
   PubMed Web of Science ®Google Scholar
• Research2Guidance. mHealth economics 2017—current status and future trends in mobile health [Published 2017; cited 2020 Oct 15]. https://research2guidance.com/product/mhealth-economics-2017-current-status-and-future-trends-in-mobile-health/.
   Google Scholar